Nicola Cadei
General Manager
Fisiopharma is authorised to produce injectable drugs in different pharmaceutical forms. Fisiopharma is a pharmaceutical company founded in 1989 as a family-run company dedicated to the development and production of injectable drugs. Our registered office and production unit is located in the industrial area of Palomonte, in the Province of Salerno, and our commercial offices are in the centre of Milan. Fisiopharma employs 124 people across the two sites and is managed by Nicola Cadei, the General Manager. As of 2018, Fisiopharma is part of Yifan Pharmaceuticals Ltd, an international biopharmaceutical company with operation and headquarters in Europe, Asia and the USA, 20 production plants and more than 5,000 employees. OUR HISTORY IN SHORT Fisiopharma Srl was founded in Palomonte (SA) in 1989 as a family-run company dedicated to the production of injectable drugs. Initially focused on the Italian hospital market, it immediately developed a strong partnership with Pharmatex Italia Srl, a commercial company headquartered in Milan and operating in the pharmaceutical business since 1977. The drugs produced by Fisiopharma were then distributed in Italian hospitals through participation in hospital tenders and abroad through distribution or licensing agreements. In 2008 Fisiopharma and Pharmatex Italia were acquired by the Polish company Bioton, a leader in insulin production. The company’s expansion into European and non-European markets continued. Fisiopharma’s international expansion and the growth of the CDMO business were thus further enhanced through collaboration, either through partnership agreements or as a third party, with American companies laying the foundation for its presence in the US market. A number of products (both proprietary and third-party) are currently awaiting approval by the FDA. Riccardo Malpede Giacinto Errante Angela Molaschi Emanuele D’Amato Vincenzo Abbatemarco Manuela Di Carlo Serenella Pastore OUR PRODUCTION SITE The Fisiopharma production site covers a total area of approximately 9,800 square metres, of which 4,000 square metres are indoors. It consists of two main buildings. Building A houses the raw materials warehouse, production departments and offices, while Building B houses the offices, new laboratories (expanded in 2021), and the recently expanded warehouse for finished products and packaging materials. Smaller buildings are dedicated to technical areas, the heating and power plant and support areas. Sensitive to the issues of energy savings and reducing environmental pollution, the company has also recently installed a solar power system. 1 1 Fisiopharma develops injectable drug formulations, including complex formulations, according to the most updated technical, quality and regulatory standards. Fisiopharma formulation development process includes small-scale preparations, development and validation of analytical methods, production of technical and compliance batches and process and equipment validations. 2 2 At Fisiopharma, the entire production cycle is managed through sampling and dispensing areas, compounding areas with different types of equipment, three filling lines, three packaging lines, two electronic inspection lines, and chemical-physical and microbiological laboratories. 3 3 Fisiopharma has an extensive international presence, distributing its products worldwide, directly or through customers, licensees or distributors. Thanks to the collaboration with Scigen Pte. Ltd, a commercial subsidiary belonging to the Yifan Group, Fisiopharma has also strengthened its presence in the Asian and South American markets. Tradition, company bonds and an eye on the future with a strong growth plan. We are Fisiopharma. EMPLOYEES vials filled with sterile powders ampoules/vials produced through aseptic filling ampoules produced through terminal sterilization years of experience gender equity are university graduates work in Quality department average length of stay in the company average employee age Fisiopharma works with different types of international customers, from small to medium-sized distributors and pharmaceutical companies to large multinational organizations.
Who is
Fisiopharma
About Us
Fisiopharma is the ideal partner for the development and production of injectable drugs.
Fisiopharma is also authorised to produce drugs of biologic origin, narcotics, corticosteroids and drugs for clinical trials.
When
Where
Who
Ownership
Who we are
01
Who
In addition to producing its own products, Fisiopharma also began to develop its contract manufacturing business, which grew considerably over the years.
In 2018, following the acquisition of Fisiopharma and Pharmatex Italia by Yifan International Ltd, the companies became part of a continuously growing multinational organization with offices, production sites and commercial presence in different areas of the world, including Europe, Asia and the United States.
Our team
02
Finance & Accounting Manager
Head of Quality Operations and QP
Chief Commercial Officer and Business Development
Head of Manufacturing Operations
Production Manager
Export Manager
Head of Quality Unit and Deputy QP
What we do
03
What
Site maintenance is performed constantly and periodically and further investments are planned in the coming years both in the production areas and in other areas.
Development of new products
Production of injectable drugs
Distribution
People
124
15
million a year
17
million a year
15
million a year
35
years
51%
women
37%
of the employees
31%
of the employees
13
years
45
years
Our customers:
As Fisiopharma, we like to establish long-lasting partnerships, developing multiple projects with each customer and always looking for new collaboration opportunities.
Let’s talk about it